All News
Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost!
Read Article
ACR25 Best Abstracts - Day 3
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.
Read Article
NEPTUNUS: Ianalumab in Sjogren's https://t.co/K9Xm51Kb5X
Finally good news in Sjogrens disease.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#ACR25 Please find my blog on update and progress of clinical trials in #Sjogren #SjD @RheumNow
https://t.co/u8pxZ5FeBX https://t.co/KAnRo3Zqnz
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What to use in future for active #Sjogren's #SjD
B cell depletion, signal attenuation
Ianalumab 2+ phase3 RCTs
Telitacept +RCT
Nipocalimab FcRn +Ph2
Dazodalibep CD40L +Ph2
+RCTs
HCQ+Lef
Rituximab
?BTKi
#ACR25 @ACRheum @RheumNow
abst#LB24, LB11
Janet Pope Janetbirdope ( View Tweet)
#Ianalumab decreases disease activity in active #Sjögren's #disease
2 phase3 DB #RCT added to #SoC in primary #SjD
>90% #Ro+
+#ESSDAI in monthly sc dosing vs placebo,
Many 2ndary outcomes improved, safe
LB#24 #ACR25 @ACRheum @RheumNow
#ACRBest https://t.co/Z4ooUg7Nos
Links:
Janet Pope Janetbirdope ( View Tweet)
#ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #Sjogren Disease presented during Late Breaking Abstract session Abstr#LB24 #SjD @RheumNow
https://t.co/ngCAglwAO0 https://t.co/PaUYsxhBKS
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjögren’s: two Phase 3 RCTs (NEPTUNUS-1 [QM], -2 [Q3M]) test Ianalumab (BAFF/BAFF-R) vs placebo.
ΔESSDAI at 48wk: Ianalumab QM > PBO, statistically significant
But ΔESSDAI ≈ 0.5–1 pt (vs PBO) below MCII (≥ 3)
Promising biology, modest clinical gain
#ACR25 @RheumNow LB24 https://t.co/8y580ch9iJ
Jiha Lee JihaRheum ( View Tweet)
Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy?
Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2
Very decent on primary (ESSDAI) & we will see this
Salivary flow only improved when some at baseline
#ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh
Links:
David Liew drdavidliew ( View Tweet)
#ACR25 Abstr#LB24 The first Phase 3 RCTs in #Sjogren meeting primary endpoint! In moderate-to-severe activity, both RCTs = improvement in ESSDAI vs PBO (pooled effect -1.2 reduction). High PBO rate. PGA, PaGA & Stimulated Salivary Flow) improved. No diff in ESSPRI/FACIT @RheumNow https://t.co/rAs6NeXDIn
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Grader-Beck et al. Ianalumab in Sjogren's disease. NEPTUNUS 1 and 2 studies. 779 patients. Met primary endpoint ESSDAI. Big placebo effect also. Patient and physician global also improved. @RheumNow #ACR25 Abstr#LB24 https://t.co/klhxXW4Jfh
Richard Conway RichardPAConway ( View Tweet)
What's new in sjogren's?
Promising phase III data of telitacicept (dual BLyS + APRIL neutralization)
Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose
Similar rates of adverse events
@RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Sjögren’s, decoded by Ab -->ESSDAI domains:
• anti-SSA → glandular
• anti-Ro52 / SCL70 → biologic activity
• anti-nucleosome → pulmonary
• anti-histone → pulmonary + cutaneous
Distinct serologic–ESSDAI patterns may guide monitoring and management
@RheumNow #ACR25 A#2295
Jiha Lee JihaRheum ( View Tweet)
#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too!
Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ClinicalPearl
Pts w #SpA ex #PsA May have
👇
#sicca #dry #eyes #dry mouth
Inflamed gallbladder without calculi
👇
Can be associated w #autoimmune disease
#POTS can be initial presentation of #SjD
IgA vasculitis—May have #cancer
#Secrets & #Pearls #ACR25 @RheumNow @ACRheum https://t.co/4SAqVYjnrD
Janet Pope Janetbirdope ( View Tweet)
Who talks to their neighbour?
+SSA / Ro talk differently to nearby cells in #SjD #salivary #glands vs NEG Ro SjD
Ro52 acts differently than Ro60
?implications for Rx response? 🤷♀️
#ACR25 @RheumNow @ACRheum #Sjogren’s
Abst#1684
#ACRBest!
Elegant work from Sara McCoy https://t.co/UWUKAxi0UW
Links:
Janet Pope Janetbirdope ( View Tweet)
#ACR25 Abstr#1401 Sjogren’s #SjD is definitely not a benign disease! Real world study using US database showed high disease burden within 12 mths of diagnosis (i.e. healthcare resource use). GC use was high (~50%). Better therapy is needed to improve outcomes @RheumNow https://t.co/MI3vQ5LByr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Need better lymphoma biomarkers in Sjögren’s?
APRIL joins BAFF as a promising candidate—high APRIL levels linked to ↑ B-cell activation, disease activity & future lymphoma.
Easily measurable, potentially targetable.
@RheumNow #ACR25 Abstract #1683
Jiha Lee JihaRheum ( View Tweet)
In Sjögren’s, cancer risk is real.
>9yr multicenter cohort (n=314), overall cancer risk ↑ (SIR 1.68), NHL >15× expected
Predictors: older age, smoking, LAD, splenomegaly, cryoglobulinemia (strongest for lymphoma).
Malignancies = 24% of deaths
@RheumNow #ACR25 Abstract #1681
Jiha Lee JihaRheum ( View Tweet)
Pregnancy risk in Sjögren’s & scleroderma
Meta-analysis (n=4,820) shows ↑ risk of miscarriage in Sjögren’s (RR 1.8) & ↑ preterm birth in SSc (RR 2.4).
Calls for preconception counseling & multidisciplinary high-risk OB care.
@RheumNow #ACR25 Abstract #1398
Jiha Lee JihaRheum ( View Tweet)
